H.C. Wainwright Thinks AzurRx BioPharma’s Stock is Going to Recover

By Carrie Williams

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on AzurRx BioPharma (AZRXResearch Report), with a price target of $2.00. The company’s shares closed last Friday at $0.54, close to its 52-week low of $0.54.

According to TipRanks.com, Chen is a top 100 analyst with an average return of 57.1% and a 52.0% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AzurRx BioPharma with a $2.00 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $2.63 and a one-year low of $0.54. Currently, AzurRx BioPharma has an average volume of 1.33M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. It focuses on MS1819-SD, and B-Lactamase program products. The company was founded on January 30, 2014 and is headquartered in Brooklyn, NY.